Cellectar Biosciences Forms Key Agreement with Ionetix for Isotope Supply
Cellectar Biosciences, Inc. (NASDAQ: CLRB), a pioneering clinical biopharmaceutical company dedicated to advancing cancer therapies, recently announced a significant multi-year supply agreement with Ionetix Corporation. This partnership focuses on the provision of two crucial alpha-emitting radioisotopes: Actinium-225 (Ac-225) and Astatine-211 (At-211).
Strategic Collaboration to Enhance Supply Chain
As part of this agreement, Ionetix will deliver a reliable supply of clinical-grade Ac-225 and At-211 isotopes that are essential for Cellectar's drug development initiatives, from clinical trials to potential product launches. This collaboration is focused on ensuring that Cellectar has access to these vital isotopes, thereby facilitating the advancement of their innovative targeted alpha therapy (TAT) candidates.
Importance of Isotope Supply to Cancer Treatment
Jarrod Longcor, COO of Cellectar Biosciences, emphasized the importance of having a dependable, scalable supply of high-quality alpha-emitting isotopes. He mentioned the company's efforts to expand its pipeline of radiotherapeutics, particularly targeting solid tumors like pancreatic cancer. The continuity of supply from Ionetix is pivotal for their objectives to advance CLR-225 into clinical trials.
Innovative Technology for Targeting Cancer
Cellectar Biosciences utilizes an advanced phospholipid ether platform technology that enhances the delivery of various isotopes directly to cancer cells. This technology allows for the identification of the most suitable isotope tailored to specific tumor types. By integrating Ac-225 and At-211 with this platform, Cellectar aims to deliver potent radiation that can effectively destroy cancer cells while minimizing damage to healthy tissue.
Ionetix's Commitment to Supporting Cellectar
David Eve, VP of medical affairs at Ionetix, shared his excitement about the collaboration, highlighting the installation of a second cyclotron at Ionetix's Michigan facility. This new cyclotron will significantly boost Ac-225 production capacity, thereby meeting the rising demand for both Ac-225 and At-211 isotopes, which are essential for the successful development of Cellectar's next-generation TATs.
About Cellectar Biosciences, Inc.
Cellectar Biosciences is a late-stage clinical radiopharmaceutical company committed to developing proprietary drugs aimed at improving cancer treatment outcomes. Their mission revolves around leveraging the unique Phospholipid Drug Conjugate™ (PDC) delivery platform to create cutting-edge cancer therapies that improve efficacy and safety.
Engaging with Cellectar and Ionetix
Cellectar continues to push the boundaries of cancer treatment through innovation and strategic partnerships. To learn more about their groundbreaking work and initiatives, individuals can visit Cellectar's official website and engage with the company across various social media platforms, including X, LinkedIn, and Facebook.
Frequently Asked Questions
What is the significance of the agreement between Cellectar and Ionetix?
The agreement ensures a reliable supply of essential isotopes for Cellectar's cancer treatment development programs.
What isotopes are involved in this collaboration?
The collaboration centers around Actinium-225 (Ac-225) and Astatine-211 (At-211), crucial for targeted alpha therapy.
How will this agreement impact cancer treatment options?
The partnership is expected to enhance the development of innovative cancer therapies, improving treatment efficacy and safety.
What technology does Cellectar use for drug delivery?
Cellectar utilizes a proprietary Phospholipid Drug Conjugate™ (PDC) platform to deliver drugs directly to cancer cells.
How can I follow updates from Cellectar Biosciences?
You can stay updated by visiting their website or following them on social media platforms like X, LinkedIn, and Facebook.
